Jaguar Health Inc
jaguar.healthJaguar Health Inc (NASDAQ: JAGX) is a pharmaceutical company that commercializes prescription drug products targeting gastrointestinal conditions. Revenue comes from product sales, with Mytesi (crofelemer) approved for HIV-related diarrhea and Gelclair launched in 2024, supplemented by royalty interests sold to lenders that require minimum royalty payments of approximately $27.0 million beginning in 2026. The company operates through its subsidiary Napo Pharmaceuticals, Inc. and has pipeline assets including crofelemer delayed-release tablets targeting chemotherapy-induced diarrhea and IBS-D, crofelemer powder for oral solution targeting short bowel syndrome, and NP-300 tablets for infectious diarrhea. As of the 10-K filed April 7, 2026, the company carried secured debt obligations to Streeterville Capital, LLC, collateralized by NP-300 intellectual property held at Napo, reflecting a debt-heavy capital structure. Sales and marketing headcount expanded in FY2025 to support the Gelclair product launch, with personnel and related benefits rising from $3.4 million in FY2024 to $5.0 million in FY2025.
Products & Services
Mytesi (crofelemer) for HIV-related diarrhea; Gelclair (launched 2024); crofelemer delayed-release tablets (pipeline, chemotherapy-induced diarrhea and IBS-D); crofelemer powder for oral solution (pipeline, short bowel syndrome and MVID); NP-300 tablets (pipeline, infectious diarrhea).
Revenue Model
Transactional prescription drug product sales, primarily Mytesi and Gelclair, with royalty interests sold to lenders generating minimum royalty payment obligations beginning July 2026.
Customers & Markets
Patients with HIV-related diarrhea, cancer patients receiving outpatient chemotherapy, patients with short bowel syndrome, IBS-D patients, and patients with infectious diarrhea. Distribution through distributors in the US market.
Geographic Exposure
Primary market is the United States; international funding activities noted in FY2025 officer travel expenses.
Financial Snapshot
Loading...
